Cargando…
Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report
BACKGROUND: Severe early-onset fetal growth restriction occurs in 0.4 % of all pregnancies, and the prognoses of these patients are dismal. Severely growth-restricted fetuses (far below 500 g) are thought to be nonviable. Since there have not been effective treatments for such fetal patients, obstet...
Autores principales: | Sakamoto, Mito, Osato, Kazuhiro, Kubo, Michiko, Nii, Masafumi, Tanaka, Hiroaki, Murabayashi, Nao, Umekawa, Takashi, Kamimoto, Yuki, Ikeda, Tomoaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100077/ https://www.ncbi.nlm.nih.gov/pubmed/27821175 http://dx.doi.org/10.1186/s13256-016-1098-x |
Ejemplares similares
-
TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial
por: Umekawa, Takashi, et al.
Publicado: (2018) -
Tadalafil treatment in mice for preeclampsia with fetal growth restriction has neuro-benefic effects in offspring through modulating prenatal hypoxic conditions
por: Tachibana, Ryota, et al.
Publicado: (2019) -
Fetal Biometric Assessment and Infant Developmental Prognosis of the Tadalafil Treatment for Fetal Growth Restriction
por: Tsuji, Makoto, et al.
Publicado: (2023) -
Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction
por: Maki, Shintaro, et al.
Publicado: (2020) -
Tadalafil Treatment Ameliorates Hypoxia and Alters Placental Expression of Proteins Downstream of mTOR Signaling in Fetal Growth Restriction
por: Tsuchiya, Kyoka, et al.
Publicado: (2020)